Cancer immunotherapy by disrupting PD-1/PD-L1 signaling | Patent Number 10266595

US 10266595 B2
Application Number16213960
Publication NumberUS 20190092863 A1
Pendency4 months, 17 days
Filled DateDec 7, 2018
Priority DateMay 15, 2012
Publication DateMar 28, 2019
Expiration DateMay 14, 2032
Inventor/ApplicantsMaria Jure-Kunkel
Jon M. Wigginton
Ashok K. Gupta
John P. Cogswell
Stacie M. Goldberg
Xi-Tao Wang
ExaminesOUSPENSKI, ILIA I
Art Unit1644
Technology Center1600
Assignments
Bristol Myers Squibb
Current
Bristol Myers Squibb
Original
Law Firm
You must be logged in to view
Login
Attorneys
Subscription-Only
View Concierge Program
Patent Prosecution report image

Empower your practice with Patexia Publication Prosecution IP Module.

Get access to our exclusive rankings and unlock powerful data.
Check our Latest ReportPurchase IP Module

Looking for a Publication Attorney?

Get in touch with our team or create your account to start exploring a network of over 120K attorneys.